E-mail: bd@sidmexinovia.com
Telefone: +918866862020
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Yurpeak 12.5mg Kwikpen
Manufacturer/Marketed By : CIPLA LTD
$274.53 $240.65
Yurpeak 12.5mg Kwikpen contains Tirzepatide as its active constituent. It belongs to the pharmacological class of GLP-1 and GIP receptor agonists and is used primarily to manage blood sugar levels...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
TIRZEPATIDE
Active Pharmaceutical Ingredient
Yurpeak 12.5mg Kwikpen
US$ 274,53
US$ 240,65
Yurpeak 12.5mg Kwikpen contains Tirzepatide as its active constituent. It belongs to the pharmacological class of GLP-1 and GIP receptor agonists and is used primarily to manage blood sugar levels in adults with type 2 diabetes. This injectable medication helps improve glycemic control by mimicking the actions of natural incretin hormones. It enhances insulin secretion while reducing the release of glucagon, helping lower blood sugar after meals. Apart from glycemic control, Yurpeak 12.5mg Kwikpen shows promise in promoting weight loss, making it beneficial for individuals with obesity or those looking to improve their metabolic health. It is typically prescribed as an adjunct to diet and exercise in patients who have not achieved desired control with oral antidiabetic medications. However, this medication is contraindicated in individuals with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Caution is advised in patients with kidney or gastrointestinal disorders. Healthcare providers should evaluate the risk factors before prescribing Yurpeak 12.5mg Kwikpen. Safety considerations include monitoring for thyroid tumors, pancreatitis, and severe hypoglycemia, especially when used alongside insulin or other antidiabetic agents. Yurpeak 12.5mg Kwikpen price in India varies by retailer and location.
Active Pharmaceutical Ingredient
Usos
• Management of type 2 diabetes mellitus in adults to improve glycemic control as an adjunct to diet and exercise.
• Support in weight management for adults with obesity or overweight conditions, particularly those with related comorbidities.
Benefícios
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
Efeitos colaterais
Yurpeak 12.5mg Kwikpen side effects include:
Efeitos colaterais mais comuns
• Pancreatitis (severe abdominal pain)
• Thyroid tumors
• Severe hypoglycemia (especially when combined with insulin)
• Kidney impairment
Efeitos colaterais comuns
• Nausea
• Vomiting
• diarrhoea
• Constipation
• Loss of appetite
• injection site reactions (redness, itching, or swelling)
Como usar
Yurpeak 12.5mg Kwikpen is available as a subcutaneous injection administered once a week. The starting dose is typically 2.5 mg injected once weekly, regardless of meal timing. Each KwikPen contains four fixed weekly doses of the selected strength. Inject on the same day each week to maintain consistent dosing. Do not attempt to split doses manually. Based on the patient’s response and tolerance, the dose may be increased to 5 mg after 4 weeks, and further titrated up to a maximum of 15 mg per week if needed. The injection should be administered into the abdomen, thigh, or upper arm, and rotating injection sites is recommended to prevent irritation. If a dose is missed, it should be taken as soon as possible within 4 days; otherwise, the next dose should be taken on the regularly scheduled day. Patients should follow their doctor’s advice on dose adjustments, especially if they experience adverse effects or fluctuations in blood sugar levels.
Conselhos de segurança
• Pregnancy: Animal studies indicate potential harm to the fetus. Use during pregnancy only if clearly necessary.
• Breast Feeding: It is unknown whether Yurpeak 12.5mg Kwikpen passes into breast milk. Breastfeeding mothers should seek medical advice.
• Lungs: No significant respiratory effects have been reported. Safe for individuals without lung complications.
• Liver: Use with caution in patients with liver impairment. Regular monitoring of liver enzymes is advisable.
• Alcohol: Consuming alcohol may increase the risk of hypoglycemia. Limit alcohol intake while using this medication.
• Driving: Dizziness or hypoglycemia may affect alertness. Exercise caution when operating machinery.
Isenção de responsabilidade
A Sidmex Inovia se esforça para fornecer informações precisas e confiáveis; no entanto, todo o conteúdo deste site, incluindo descrições e composições de produtos, tem caráter meramente informativo e não deve ser considerado um substituto para aconselhamento, diagnóstico ou tratamento médico profissional.
Recomenda-se aos usuários que consultem um profissional de saúde qualificado antes de tomar qualquer decisão médica. As informações fornecidas não devem ser usadas para autodiagnóstico ou automedicação.
Todos os produtos listados destinam-se estritamente a consultas B2B e em grandes quantidades. A Sidmex Inovia não promove o uso direto pelo consumidor e visa apoiar, e não substituir, a relação entre o profissional de saúde e o paciente.
Os nomes de produtos, marcas comerciais e marcas pertencem aos seus respectivos proprietários, e seu uso não implica qualquer afiliação ou endosso. A Sidmex Inovia não se responsabiliza por quaisquer consequências decorrentes do uso das informações fornecidas neste site.